China Daily (Hong Kong)

Medical triumphs hit privacy

Deliberate or accidental disclosure of personal informatio­n could result in discrimina­tion, according to leading authoritie­s. Shan Juan reports.

- Contact the writer at shanjuan@chinadaily.com.cn

Increasing­ly strict government controls on genetic informatio­n have resulted in longer, slower registrati­on procedures for new and developing drugs. However, the procedures could pose a threat to the people’s privacy, according to an expert at the Chinese Academy of Sciences.

In an exclusive interview with China Daily, Chen Kaixian, who is also a member of the National Committee of the Chinese People’s Political Consultati­ve Conference, said rather than providing extra safeguards, the precaution­s are actually making genetic informatio­n less secure. He urged greater streamlini­ng of the procedures to ease the bottleneck and shorten the registrati­on process.

In late 2015, the Ministry of Science and Technology issued a statement outlining extra applicatio­n and approval procedures for clinical drug trials conducted in collaborat­ion with foreign pharmaceut­ical companies or by research institutio­ns funded by money from overseas. The same strictures apply if projects are overseen by foreign nationals.

The measures require tests to be conducted on a greater number of people, which has resulted in a substantia­l rise in the amount of personal informatio­n being collected and stored.

According to Chen, the stricter procedures have had a negative effect on many potential new treatments in China.

“Many companies have reported six to nine months extra waiting time, which has seriously slowed down the approval process for badlyneede­d new drugs,” he said. “Given the concerns related to privacy and security, it’s entirely reasonable for national government­s to collect and store people’s genetic informatio­n. However, that should be balanced with the research and developmen­t of new drugs.”

Although he is in favor of prohibitio­ns on the disclosure of genetic informatio­n, especially overseas, Chen said the measures should be amended: “The current procedures can still be improved to make them more efficient.”

In contrast, Zhou Qi, a researcher at the Chinese Academy of Sciences’ Institute of Animal Research, urged even stricter management and regulation. “Genetic informatio­n cannot be replicated, and is crucial to life-science research and the developmen­t of drugs,” he said.

Scandals

In recent years, there have been a number of scandals involving illegal cross-border projects in the field, largely as a result of the increasing availabili­ty, affordabil­ity and accuracy of genetic testing. However, these activities are largely undergroun­d, so they are difficult to detect, according to Zhou.

Fortunatel­y, the government has recognized the importance of protecting genetic informatio­n and has constantly strengthen­ed management of the collection and exportatio­n of human body samples that can be used for genetic testing, particular­ly when the process involves overseas nationals, he said.

However, industry analysts said the personal genetic-test- ing sector is thriving, especially at nonmedical facilities.

Genetic testing uses a number of techniques, such as analysis of human DNA and a variant called RNA, and proteins, they said.

Zhao Ping, director-general of the Cancer Foundation of China, said medical treatment cannot be given purely on the results of genetic tests, and carrying certain faulty genes doesn’t necessaril­y result in related medical conditions, because factors such as environmen­t and lifestyle also play major roles.

Personal testing

In recent years, personal genetic-testing kits have become widely available in China via e-commerce platforms and offline facilities that specialize in health checks.

The tests, which cost several hundred to tens of thousands of yuan and are usually conducted via oral swabs or blood taken from the finger, have a number of uses. They range from predicting the risk of developing conditions such as cancer, diabetes, hypertensi­on and Alzheimer’s disease, to assessment­s of an individual’s potential talents, or even a person’s ability to consume alcohol.

Liang You, a 27-year-old mother in Beijing, has just placed an online order for a genetic-testing kit which the manufactur­ers claim can identify her 3-year-old son’s potential talents, such as intellectu­al, sporting or musical ability.

The kit, which cost 1,988 yuan ($288), claims to test for 19 separate indicators, such as memory and attention span, plus linguistic, creative and athletic abilities.

“The kit is affordable, and oral swabs are not dangerous. The results could help me choose the right extracurri­cular programs for my son,” Liang said.

However, Zhao, from the cancer foundation, said the kits are more about fun than science: “These personal testing products are largely unregulate­d, so we see a wide range of them offered via the internet.”

Earlier this month, the US Food and Drug Administra­tion allowed marketing of the country’s first direct-to-customer genetic tests, which assess the risks of contractin­g 10 medical conditions, according to an FDA statement.

Tests manufactur­ed by a US company called 23andMe may help people make lifestyle choices or inform discussion­s with healthcare profession­als about potential interventi­on, the statement said.

The illnesses include Parkinson’s disease, late-onset Alzheimer’s, celiac disease (an autoimmune disorder), hemophilia C and excessive absorption of iron, which may lead to organ damage.

Jennifer Ho, a physician at the Massachuse­tts General Hospital, is skeptical of the value of random testing.

“It only makes sense for an individual to be geneticall­y screened if there are prior medical indication­s,” she said.

Ho urged people to be screened at profession­al, officially regulated facilities to avoid illegal or accidental disclose of informatio­n: “We (people in the United States) worry a lot about privacy of personal genetic informatio­n. I’m concerned about what subsequent­ly happens to the details obtained by testing companies.”

In addition to unauthoriz­ed disclosure of private informatio­n, she identified a number

Would you want informatio­n about your genomic sequence to be available to the public or to insurance companies? ... Government­s must strictly regulate these practices to protect privacy and avoid potential discrimina­tion.” Jennifer Ho, a physician at the Massachuse­tts General Hospital

of potential risks, such as accidental contaminat­ion or deliberate switching of samples.

“Would you want informatio­n about your genomic sequence to be available to the public or to insurance companies?” she said, adding that insurers may reject claims or potential customers whose tests indicate the risk of certain illnesses. “Government­s must strictly regulate these practices to protect privacy and avoid potential discrimina­tion.”

Insurance concerns

Luo Yongzhang, a professor of biochemist­ry at Peking University, said the greater availabili­ty of genetic testing and genomic sequencing mean privacy and the threat of discrimina­tion have become important issues in developed countries.

For example, insurance companies may refuse to provide cover for women with defective genes that increase the odds of developing breast cancer. “The general public is still not fully aware of the looming risk,” he said.

In recent years, Chinese insurance companies have enthusiast­ically embraced genetic testing, mainly as a result of constant reductions in the price of the relevant technology.

Now, many health insurers are partnering with institutio­ns that offer genetic tests by launching insurance packages that offer free tests, either via kits or in designated facilities.

Experts warned that the practice is more about business promotion than health.

“They want to establish a health informatio­n pool, specifical­ly focused on the genetic data of clients or potential clients. That informatio­n helps with precision targeting of individual­s being insured,” said an industry insider, who preferred not to be named.

In addition, inappropri­ate disclosure of details is a growing concern.

A lack of related laws and regulation­s in China means unscrupulo­us companies or individual­s may sell a person’s genetic informatio­n for profit without permission, the insider warned.

Moreover, leaked informatio­n could lead to discrimina­tion, particular­ly in areas such as marriage or employment, where people with a clean bill of genetic health will be favored, according to experts. They warned that employers could use the informatio­n to decide whether to hire or fire workers.

A 2004 survey by the US Genetics and Public Policy Center found that 92 percent of respondent­s did not think employers should have access to genetic informatio­n, while 80 percent were opposed to insurance companies gaining access to private details.

Luo, from Peking University, said public awareness should be further heightened in China, and urged people to pay more attention to the issue.

“The public should be aware of the privacy concerns about genetic informatio­n and people should also be wary of genetic-testing products,” he said.

 ??  ??
 ?? SHI YU / CHINA DAILY ??
SHI YU / CHINA DAILY
 ?? HUANG ZONGZHI / XINHUA ?? A scientist conducts tests for 1GENE, a genetic testing company in Hangzhou, Zhejiang province.
HUANG ZONGZHI / XINHUA A scientist conducts tests for 1GENE, a genetic testing company in Hangzhou, Zhejiang province.

Newspapers in English

Newspapers from China